<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03901196</url>
  </required_header>
  <id_info>
    <org_study_id>38RC18.134</org_study_id>
    <secondary_id>2019-A00070-57</secondary_id>
    <nct_id>NCT03901196</nct_id>
  </id_info>
  <brief_title>Multi-elemental Imaging of Lung Tissues With LIBS (Laser-induced Breakdown Spectroscopy)</brief_title>
  <acronym>MEDICO-LIBS</acronym>
  <official_title>Multi-elemental Imaging of Lung Tissues With LIBS (Laser-induced Breakdown Spectroscopy) : a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the feasibility of performing a multi-elemental imaging analysis of lung specimens
      from patients with ILDs, with an technology named LIBS (Laser Induced-Breakdown Spectroscopy)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is a major health problem due to the environmental and occupational related exposures
      to mineral particles, metals, and dust. The impact on health is considerable in terms of
      prevalence, morbidity and healthcare costs. Pathologists rarely report the presence of a
      possible mineral or metal-related etiology in a specimen by lack of available and convenient
      technology. Therefore, several respiratory diseases are considered idiopathic.

      Interstitial lung disease (ILD), also known as diffuse parenchymal lung disease (DPLD) is a
      group of lung diseases affecting the interstitium (the tissue and space around the air sacs
      of the lungs). In France, 15.000 new cases of ILD are diagnosed each year. ILD may be
      classified according to the cause. Idiopathic ILD are ILD of unknown causes. The most
      frequent idiopathic ILD are sarcoidosis and idiopathic pulmonary fibrosis (IPF).These two
      diseases are the core topic of the present study since they may relate to important mineral
      or metal exposure.

      The overall goal of this MEDICO-LIBS study is to evaluate the feasibility of using a
      laser-induced breakdown spectroscopy (LIBS)-based instrument to image(ie, identify, localize
      and possibly quantify) metals within selected human specimens with ILDs.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 16, 2019</start_date>
  <completion_date type="Anticipated">May 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Generation of multi-elemental images in tissues with LIBS</measure>
    <time_frame>Within a month after reception of the biopsy by the analytical laboratory</time_frame>
    <description>Evaluation of the feasibility of collecting and describing LIBS multi-elemental images of lung specimens originating from patients with ILDs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of elemental distribution in the specimens</measure>
    <time_frame>Within a month after reception of the biopsy by the analytical laboratory</time_frame>
    <description>Comprehensive chemical characterization of both endogenous and exogenous elements for each specimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interpretation of the elemental maps</measure>
    <time_frame>Within a month after reception of the biopsy by the analytical laboratory</time_frame>
    <description>Understanding of the elemental distribution according to the clinical data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the elemental distributions with results of other mineralogical investigations</measure>
    <time_frame>Within a month after reception of the biopsy by the analytical laboratory</time_frame>
    <description>Only for patients who previously benefited from other mineralogical investigations (eg, SEM-EDX), comparison of mineralogical analysis obtained with the elemental distributions obtained with LIBS</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Interstitial Lung Disease</condition>
  <condition>Sarcoidosis</condition>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Interstitial Lung Disease</arm_group_label>
    <description>Ex : sarcoidosis, IPF</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Elemental analysis</intervention_name>
    <description>LIBS multi elemental analysis of the specimen</description>
    <arm_group_label>Interstitial Lung Disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with Interstitial Lung Disease
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with ILD

          -  Patient informed, and agreed to participate

        Exclusion Criteria:

          -  Patient opposed to participating in the study.

          -  Patient without available specimen.

          -  Patient under legal protection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Busser, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Grenoble Alpes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Benoit Busser, PharmD, PhD</last_name>
    <phone>+33 4 76 76 89 39</phone>
    <email>bbusser@chu-grenoble.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grenoble Alpes University Hospital</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Bonneterre, MD, PhD</last_name>
      <email>VBonneterre@chu-grenoble.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sébastien Quetant, MD</last_name>
      <email>SQuetant@chu-grenoble.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHRU de LILLE</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cecile Chenivesse, MD, PhD</last_name>
      <email>cecile.chenivesse@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Lyon HCL - GH Sud</name>
      <address>
        <city>Lyon</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nathalie Freymond, MD</last_name>
      <email>nathalie.freymond@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Cottin, MD, PhD</last_name>
      <email>vincent.cottin@chu-lyon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Busser B, Moncayo S, Trichard F, Bonneterre V, Pinel N, Pelascini F, Dugourd P, Coll JL, D'Incan M, Charles J, Motto-Ros V, Sancey L. Characterization of foreign materials in paraffin-embedded pathological specimens using in situ multi-elemental imaging with laser spectroscopy. Mod Pathol. 2018 Mar;31(3):378-384. doi: 10.1038/modpathol.2017.152. Epub 2017 Nov 17.</citation>
    <PMID>29148536</PMID>
  </results_reference>
  <results_reference>
    <citation>Busser et al., Coord Chem Rev, 2018, 358, p70</citation>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 28, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Laser Induced Breakdown Spectroscopy</keyword>
  <keyword>Multi elemental imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

